Related Experiment Video

Updated: May 18, 2026

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

TLE1 is an anoikis regulator and is downregulated by Bit1 in breast cancer cells

Chris Brunquell1, Hector Biliran, Scott Jennings

  • 1Center for Nanomedicine, Sanford-Burnham Medical Research Institute, Santa Barbara, California, USA.

Molecular Cancer Research : MCR
|September 7, 2012
PubMed

Insights

Transducin-like enhancer of split 1 (TLE1) protein regulates anoikis, a form of apoptosis. TLE1 promotes anoikis resistance and anchorage-independent growth in breast cancer cells, suggesting a role in tumor progression.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Biology

Background:

  • Transducin-like enhancer of split 1 (TLE1) is a transcriptional repressor involved in cell survival and anti-apoptosis.
  • Anoikis, apoptosis induced by loss of cell adhesion, is a critical process in normal tissue homeostasis and cancer progression.
  • TLE1's role in anoikis regulation, particularly in breast cancer, remains largely unexplored.

Purpose of the Study:

  • To investigate the role of TLE1 in anoikis regulation in normal mammary epithelial and breast carcinoma cells.
  • To elucidate the molecular mechanisms by which TLE1 influences anoikis resistance and anchorage-independent growth in breast cancer.

Main Methods:

  • Analysis of TLE1 expression in mammary epithelial and breast cancer cells under conditions of cell detachment.
  • Genetic manipulation of TLE1 expression (overexpression and downregulation) to assess its impact on anoikis resistance.
  • Investigation of the TLE1-mediated inhibition of the Bit1 anoikis pathway, including interactions with AES and Bit1.
  • Immunohistochemical analysis of TLE1 expression in human breast tumor tissues.

Main Results:

  • TLE1 expression is downregulated during anoikis induction in normal mammary epithelial cells, while its forced expression confers anoikis resistance.
  • TLE1 is upregulated in breast cancer cells upon detachment and promotes their anoikis resistance and anchorage-independent growth.
  • TLE1 inhibits the Bit1 anoikis pathway by sequestering AES in the nucleus, thereby preventing the formation of a proapoptotic complex.
  • Mitochondrial release of Bit1 or its expression in the cytoplasm induces TLE1 degradation, suggesting a feedback mechanism.

Conclusions:

  • TLE1 plays a significant role in promoting anoikis resistance in breast cancer cells.
  • TLE1's mechanism involves inhibiting the Bit1 pathway and protecting cancer cells from anoikis-induced death.
  • TLE1 upregulation in invasive breast tumors suggests its potential as a biomarker and therapeutic target in breast cancer.

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...